ScoreWhy is TherapeuticsMD, Inc. ?
1
With a growth in Net Sales of 22.55%, the company declared Outstanding results in Sep 25
- The company has declared positive results for the last 3 consecutive quarters
- NET SALES(HY) At USD 1.74 MM has Grown at 122.28%
- PRE-TAX PROFIT(Q) At USD 0.08 MM has Grown at 164.06%
- NET PROFIT(Q) At USD 0.08 MM has Grown at 173.05%
2
With ROE of 0.73%, it has a attractive valuation with a 0.92 Price to Book Value
- Over the past year, while the stock has generated a return of 164.65%, its profits have risen by 107.4% ; the PEG ratio of the company is 0.2
3
High Institutional Holdings at 30.37%
- These investors have better capability and resources to analyse fundamentals of companies than most retail investors.
4
Market Beating Performance
- The stock has generated a return of 164.65% in the last 1 year, much higher than market (S&P 500) returns of 13.68%
Real-Time Research ReportHow much should you buy?
- Overall Portfolio exposure to TherapeuticsMD, Inc. should be less than 10%
- Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock
Is TherapeuticsMD, Inc. for you?
High Risk, Medium Return
Absolute
Risk Adjusted
Volatility
TherapeuticsMD, Inc.
164.65%
0.12
81.23%
S&P 500
13.68%
0.71
19.28%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
-46.28%
EBIT Growth (5y)
14.69%
EBIT to Interest (avg)
-4.73
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.18
Sales to Capital Employed (avg)
0.28
Tax Ratio
2.86%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
30.37%
ROCE (avg)
0
ROE (avg)
0
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
25
Industry P/E
Price to Book Value
0.92
EV to EBIT
-7.28
EV to EBITDA
-8.54
EV to Capital Employed
0.89
EV to Sales
6.82
PEG Ratio
0.23
Dividend Yield
NA
ROCE (Latest)
-12.24%
ROE (Latest)
0.73%
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Mildly Bullish
RSI
No Signal
Bearish
Bollinger Bands
Bullish
Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Mildly Bearish
Bullish
Dow Theory
Mildly Bullish
Mildly Bullish
OBV
Mildly Bearish
Mildly Bullish
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend29What is working for the Company
NET SALES(HY)
At USD 1.74 MM has Grown at 122.28%
PRE-TAX PROFIT(Q)
At USD 0.08 MM has Grown at 164.06%
NET PROFIT(Q)
At USD 0.08 MM has Grown at 173.05%
ROCE(HY)
Highest at 0.27%
DEBTORS TURNOVER RATIO(HY)
Highest at 0.8 times
RAW MATERIAL COST(Y)
Fallen by -6.52% (YoY
0What is not working for the Company
NO KEY NEGATIVE TRIGGERS
Here's what is working for TherapeuticsMD, Inc.
Net Sales
At USD 1.74 MM has Grown at 122.28%
Year on Year (YoY)MOJO Watch
Sales trend is very positive
Net Sales (USD MM)
Pre-Tax Profit
At USD 0.08 MM has Grown at 164.06%
over average net sales of the previous four periods of USD -0.13 MMMOJO Watch
Near term Pre-Tax Profit trend is very positive
Pre-Tax Profit (USD MM)
Net Profit
At USD 0.08 MM has Grown at 173.05%
over average net sales of the previous four periods of USD -0.11 MMMOJO Watch
Near term Net Profit trend is very positive
Net Profit (USD MM)
Debtors Turnover Ratio
Highest at 0.8 times and Grown
In each half year in the last five Semi-Annual periodsMOJO Watch
Company has been able to sell its Debtors faster
Debtors Turnover Ratio
Raw Material Cost
Fallen by -6.52% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin
Raw Material Cost as a percentage of Sales
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
